Sevoflurane

Generic Name: Sevoflurane

Brand Names: Sevorane, Sojourn, Ultane

Drug Type: Small Molecule

Chemical Formula: C_₄H_₃F_₇O

CAS Number: 28523-86-6

Unique Ingredient Identifier: 38LVP0K73A

Background: Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition coefficient. Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 1996. Sevoflurane is three times more potent than desflurane, but has lower potency compared to halothane and isoflurane. Unlike other volatile anesthetics, sevoflurane has a pleasant odor and does not irritate the airway. The hemodynamic and respiratory depressive effects of sevoflurane are well tolerated, and most patients receiving this anesthetic agent present little toxicity. Therefore, it can be used for inhalational induction in adults and children for a wide variety of anesthetic procedures.

Indication: Sevoflurane is used for the induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery.

Associated Conditions: -

Associated Therapies: General Anesthesia, Induction and Maintenance of General Anesthesia

Clinical Trials

The Effect of Desflurane vs Sevoflurane on Perioperative Respiratory Complications in Laryngeal Mask Airway Anesthesia

Phase 4

Conditions: Anesthesia; Adverse Effect
Laryngeal Masks
Respiratory System Abnormalities

Interventions: Drug: Desflurane
Drug: Sevoflurane

First Posted Date: 2016-12-30

Last Posted Date: 2018-12-28

Lead Sponsor: Chiang Mai University

Target Recruit Count: 220

Registration Number: NCT03006250

Locations: 🇹🇭
Chiang Mai University, Chiang Mai, Thailand

Efficacy of Opioid-free Anesthesia in Reducing Postoperative Respiratory Depression in Children Undergoing Tonsillectomy

Phase 3

Completed

Conditions: Anesthesia
General Anesthesia
Analgesics, Opioid
Postoperative Complications
Pathologic Processes
Physiologic Effects of Drugs
Narcotics
Analgesics
Sleep Disordered Breathing
Obstructive Sleep Apnea of Child

Interventions: Drug: Acetaminophen, gabapentin
Drug: Acetaminophen
Drug: Ketamine , Lidocaine , Dexmedetomidine
Drug: Fentanyl, Dexmedetomidine
Drug: Dexamethasone , Ondansetron
Drug: Sevoflurane, Fentanyl
Drug: Sevoflurane

First Posted Date: 2016-12-09

Last Posted Date: 2021-08-10

Lead Sponsor: University of Saskatchewan

Target Recruit Count: 50

Registration Number: NCT02987985

Locations: 🇨🇦
Royal University Hospital, Saskatoon, Saskatchewan, Canada

Evaluating Pain Outcomes of Ketorolac Administration in Children Undergoing Circumcision

Phase 1

Completed

Conditions: Pain, Postoperative
Phimosis
Paraphimosis
Balanitis

Interventions: Drug: Bupivacaine
Drug: Sevoflurane
Drug: Acetaminophen
Drug: Ibuprofen
Drug: Ketorolac

First Posted Date: 2016-11-28

Last Posted Date: 2018-06-29

Lead Sponsor: Alberta Children's Hospital

Target Recruit Count: 30

Registration Number: NCT02973958

Locations: 🇨🇦
Alberta Children's Hospital, Calgary, Alberta, Canada

The Effects of Inhalational Anaesthetics in Cognitive Functions in Down Syndrome Patients

Phase 2

Completed

Conditions: Down Syndrome

Interventions: Drug: Sevoflurane
Drug: Desflurane

First Posted Date: 2016-11-22

Last Posted Date: 2020-06-09

Lead Sponsor: Asklepieion Voulas General Hospital

Target Recruit Count: 39

Registration Number: NCT02971254

Locations: 🇬🇷
Gkliatis Emmanouil, Athens, Greece

Sevoflurane in Subarachnoidal Haemorrhage

Phase 2

Withdrawn

Conditions: Subarachnoid Haemorrhage (SAH)

Interventions: Drug: Sevoflurane
Drug: Propofol
Device: MIRUS™System
Drug: Midazolam

First Posted Date: 2016-10-27

Last Posted Date: 2020-06-02

Lead Sponsor: University of Zurich

Registration Number: NCT02946437

Locations: 🇨🇭
University Hospital Zurich, Zurich, Switzerland

Comparison of Postoperative Outcome After Sevoflurane and Propofol Anaesthesia

Phase 4

Completed

Conditions: Postoperative Cognitive Dysfunction

Interventions: Drug: sevoflurane
Drug: propofol

First Posted Date: 2016-10-13

Last Posted Date: 2018-07-10

Lead Sponsor: Xinqiao Hospital of Chongqing

Target Recruit Count: 300

Registration Number: NCT02931877

Locations: 🇨🇳
Xinqiao Hospital, Third Military Medical University, Chongqing, Chongqing, China
🇨🇳
Xinan Hospital, Third Military Medical University, Chongqing, Chongqing, China
🇨🇳
Daping Hospital, Third Military Medical University, Chongqing, Chongqing, China